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A B S T R A C T
Background: Mutations in MYBPC3 are the most common cause of hypertrophic cardiomyopathy (HCM). These
mutations produce dysfunctional protein that is quickly degraded and not incorporated in the myoﬁlaments.
Most patients are heterozygous and allelic expression diﬀers between cells. We hypothesized that this would lead
to cell-to-cell variation in cardiac myosin binding protein-C (cMyBP-C, encoded byMYBPC3 gene) protein levels.
Methods: Twelve HCM patients were included (six had no sarcomere mutations (HCMsmn) and served as the
control group and six harbored mutations in the MYBPC3 gene (MYBPC3mut). Western blot and RNA sequencing
analysis of cardiac tissue lysates were performed to detect overall cMyBP-C protein and mRNA levels. Cellular
expression of cMyBP-C and α-actin was obtained by immunoﬂuorescence staining. Quantiﬁcation of cell-to-cell
variation of cMyBP-C expression between cardiomyocytes was measured by determining the ratio of cMyBP-C:α-
actin stained area of each cell.
Results: Protein and mRNA analysis revealed signiﬁcantly reduced cMyBP-C levels in MYBPC3mut patients
compared with HCMsmn patients (0.73 ± 0.09 vs. 1.0 ± 0.15, p < .05; 162.3 ± 16.4 vs. 326.2 ± 41.9
RPKM, p= .002), without any sign of truncated proteins. Immunoﬂuorescence staining of individual cardio-
myocytes in HCMsmn patients demonstrated homogenous and equal cMyBP-C:α-actin staining ratio. In contrast,
MYBPC3mut patients demonstrated inhomogeneous staining patterns with a large intercellular variability per
patient. Coeﬃcient of variance for cMyBP-C/α-actin staining for each patient showed a signiﬁcant diﬀerence
between both groups (17.30 ± 4.08 vs. 5.18 ± 0.65% in MYBPC3mut vs. HCMsmn, p= .02).
Conclusion: This is the ﬁrst study to demonstrate intercellular variation of myoﬁlament cMyBP-C protein ex-
pression within the myocardium from HCM patients with heterozygous MYBPC3 mutations.
1. Introduction
Hypertrophic cardiomyopathy (HCM), the most common genetic
cardiomyopathy with an estimated prevalence of 1:200 [1], is
characterized by isolated, asymmetric left ventricular hypertrophy
(LVH), diastolic dysfunction and an increased risk on arrhythmias.
Mutations in the genes encoding the sarcomeric thick ﬁlament com-
ponents cardiac myosin binding protein-C (cMyBP-C) and β-myosin
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heavy chain (MYBPC3 and MYH7, respectively) account for ~80% of
mutations [2].
Two disease mechanisms are described in HCM: 1) poison poly-
peptides, in which point mutations directly result in changes in protein
function, and 2) haploinsuﬃciency, where the mutated allele produces
truncated proteins and the other allele cannot fully compensate. Most
HCM-associated MYBPC3 mutations (MYBPC3mut) are predicted to lead
to truncated proteins [3]. These truncated proteins are suspected to be
degraded rapidly since they could not be detected in myectomy samples
from HCM patients [4]. This means that all protein which is expressed
originates from the healthy allele. The loss of full-length cMyBP-C
proteins leads to a reduction of cMyBP-C expression of 30% (i.e. hap-
loinsuﬃciency) [4].
It has recently been shown that when expressing a gene, cells
transcribe both alleles independently. Allelic transcription occurs in a
stochastic manner, where one cell might favor one allele while the next
cell favors the other allele and this preference can change over time [5].
This burst-like, stochastic on/oﬀ-switching of allele transcription
should average out over time, but in case of heterozygosity with protein
product of diﬀerent stability, it can lead to variable expression of
healthy and mutant proteins. This was recently shown by Kraft and
colleagues [6,7]. Patients with heterozygous HCM-associated MYH7
gene mutation demonstrated a variable healthy:mutant ratio of mRNA
expression in cardiomyocytes from the same heart [6]. This was pos-
tulated to result in a variable expression of MYH7 mutant protein. In
case of MYBPC3 truncating mutations where the mutant allele does not
produce functional protein [4,8], averaging out over time does not
occur and cell-to-cell diﬀerences in cMyBP-C protein expression are
Fig. 1. Protein and mRNA analysis. A. Western immunoblot of MYBPC3mut (n=6) and HCMsmn (n=6) patients showing only expression of the full-length cMyBP-C
protein with no signs of truncated proteins formed in MYBPC3mut patients. B. Signiﬁcantly lower expression of cardiac myosin binding protein-C normalized to α-
actin in six MYBPC3mut and HCMsmn patients. cMyBP-C/α-actin in HCM is set to 1. C. Reduced mRNA expression level of MYBPC3 in MYBPC3mut patients (n=16)
compared with HCMsmn (n=10). ACTC1 mRNA levels were not changed.
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expected. The objective of this study was to investigate whether the
most common cause of HCM, heterozygousMYBPC3mutations give rise
to a variable myoﬁlament cMyBP-C expression pattern.
2. Methods
2.1. Study population
Studies were performed in septal myectomy samples from six pa-
tients with frameshift and missense mutations inMYBPC3 (MYBPC3mut)
and six sarcomere mutation negative, phenotype positive patients
(HCMsmn) (see Fig. 2 for genetic information). All patients were
symptomatic with an increased resting left ventricular outﬂow tract
gradient despite optimal medical treatment and were indicated to un-
dergo septal myectomy. All samples were immediately frozen and
stored in liquid nitrogen. The study protocol was approved by the local
ethics committees, and written informed consent was obtained.
For expanded methods see the Online Supplemental Material.
3. Results
3.1. Study population
The study population consisted of twelve HCM patients (six
MYBPC3mut; six HCMsmn) who underwent a surgical septal myectomy
procedure. MYBPC3mut were signiﬁcantly younger and were more often
men compared to HCMsmn patients (29 ± 7 vs. 61 ± 7 years,
p < .001 and 6 males vs. 4 males, p= .02, respectively). Although all
patients underwent a septal myectomy procedure to relief left ven-
tricular outﬂow tract obstruction, MYBPC3mut subjects demonstrated a
signiﬁcantly higher septal wall thickness compared to HCMsmn (28 ± 8
vs. 18 ± 3mm, p= .02), see Table S1 for additional clinical details.
3.2. Reduced cMyBP-C protein and mRNA level in cardiac tissue with
MYBPC3 mutation
MYBPC3mut patients were heterozygous for frameshift (n=5) and
missense (n=1) mutations. As shown before [4], no truncated protein
products were detected (Fig. 1A). Haploinsuﬃciency was conﬁrmed
since total cMyBP-C protein level was signiﬁcantly lower in MYBPC3mut
compared with HCMsmn patients (0.73 ± 0.09 vs. 1.0 ± 0.15,
p= .04) (Fig. 1B). MYBPC3mut patients revealed a signiﬁcant lower
mRNA level of MYBPC3 gene expression compared with HCMsmn
(p= .002 for MYBPC3) while ACTC1 expression was unchanged
(p= .7, Fig. 1C).
3.3. Immunoﬂuorescence staining of cardiomyocytes
As the truncated protein products of the nonsense MYBPC3 muta-
tions were not detected, any cMyBP-C protein expression present in
MYBPC3mut cardiomyocytes has to originate from the healthy allele.
Therefore the protein expression ratio of healthy:mutant allele was
quantiﬁed by measuring the amount of cMyBP-C. Fig. 2 depicts a re-
presentative cardiomyocyte of a HCMsmn (panel A) and MYBPC3mut
(panel B) patient. The cardiomyocyte in Fig. 2A demonstrates a
homogenous cMyBP-C (white) and α-actin (green) staining, while
MYBPC3mut staining was heterogeneous (Fig. 2B). Cell width in both
patient groups was similar and excluded the possibility that the absence
of cMyBP-C staining could be caused by insuﬃcient antibody penetra-
tion (see Fig. S4). More rod shaped cells were seen in MYBPC3mut
compared to HCMsmn (Fig. S5). Fig. 6 of the Supplemental Material
shows additional images of cardiomyocytes of cMyBP-C staining in
HCMsmn and MYBPC3mut patients.
3.4. Cell-to-cell variability of cardiac myosin binding protein-C protein
levels in MYBPC3mut
To quantify the variability of cMyBP-C protein level between car-
diomyocytes from the same patient, cMyBP-C:α-actin staining area
ratio was measured in 15 to 27 cardiomyocytes per patient, as depicted
in Fig. 2C and D. HCMsmn patients demonstrate homogenous and equal
ratio of cMyBP-C:α-actin ratio of stained area in all cardiomyocytes
(Fig. 2C). In contrast, MYBPC3mut patients displayed a large inter-
cellular variability of cMyBP-C staining relative to α-actin (Fig. 2D).
The variation of the cMyBP-C staining pattern demonstrated a large
diﬀerence in staining pattern between MYBPC3mut compared with
HCMsmn cells (Fig. S7, panels A, B and C), and cMyBP-C free patches
varied in length (Fig. S7, panel D). Distribution of cMyBP-C/α-actin
stained ratio showed a normal distribution (Fig. S8).The variation in
ratio of cMyBP-C/α-actin stained area per cell per patient was quanti-
ﬁed by determining the coeﬃcient of variance of cMyBP-C/α-actin
ratio for each patient. This demonstrated a signiﬁcant diﬀerence in
variation of protein expression between the cardiomyocytes in both
patient groups (5.18 ± 0.65 vs. 17.30 ± 4.08%, p= .02) (Fig. 2E).
4. Discussion
This is the ﬁrst study to demonstrate intercellular variation of
cMyBP-C myoﬁlament protein expression due to mutations in MYBPC3
within the myocardium from HCM patients.
The concept underlying variable expression is that a cell pre-
dominantly transcribes one allele of a gene, which is “chosen” at
random, which was demonstrated by single cell sequencing [9]. In
healthy subjects it does not matter from which allele a cell transcribes
its protein as this process occurs stochastically. In case of a mutant
allele and a wild-type allele (such as in heterozygous HCM patients),
this will lead to a certain number of cardiomyocytes with a relatively
high level of mutant protein and other cardiomyocytes with very little
mutant protein. This was recently shown to occur at the mRNA level in
the MYH7 R723G mutation [6]. As MYH7 mutations are point muta-
tions, this variable expression pattern was not validated on protein le-
vels yet. Western blot analysis in this study conﬁrmed previous ﬁndings
that the truncated protein products of the mutated allele are degraded
in the cardiac tissue [10] (Fig. 1A).
The amount of healthy cMyBP-C in a MYBPC3mut cardiomyocyte is
the result of the amount of transcription from the healthy allele, the
translation eﬃciency and the protein turnover rate. Helms and collea-
gues demonstrated a paradoxical upregulation of mRNA in samples
with truncating mutations, which was assumed to be a compensatory
mechanisms as an attempt to maintain full-length cMyBP-C [11].
However, we observed a decreased expression of cMyBP-C at mRNA
and protein level in MYBPC3mut conﬁrming previous observations
[4,8]. In accordance, transduction of full-length and truncating mutant
MYBPC3 in engineered heart tissue, to mimic a heterozygous mutation,
showed cMyBP-C haploinsuﬃciency [12]. It has recently been shown
by Lewis and colleagues that for maintenance of the sarcomere, a highly
deﬁned spatial control of protein translation and degradation is present
[13]. They showed that at individual sarcomeres throughout the cell,
protein translation and degradation machinery was present. In
MYBPC3mut we know that transcription and therefore translation of
MYBPC3 is impaired, but also that there are changes in protein de-
gradation, and therefore turnover [14]. Changes in microtubule archi-
tecture are known to occur in HCM [15], which are important for de-
livery of the translation and degradation machinery throughout the cell
[13]. The loss of spatial control of protein translation and degradation
in conjunction with the lower levels of transcription likely all con-
tribute to the diverse cMyBP-C staining patterns observed in the car-
diomyocytes from MYBPC3mut. In HCMsmn homogeneous expression of
cMyBP-C with low levels of cell-to-cell variation were seen, indicating
that the observed eﬀects are speciﬁc for MYBPC3 mutations. These
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Fig. 2. Cell-to-cell variability. Typical examples of cardiomyocytes with double-staining of cardiac myosin binding protein-C and α-actin in a HCMsmn (panel A) and
MYBPC3mut (panel B) patient. Heterogeneous expression of cardiac myosin binding protein-C in MYBPC3mut, compared to HCMsmn patients in which staining of
cardiac myosin binding protein-C is homogenously distributed. C. Heterogeneity of the cMyBP-C:α-actin ratio in HCMsmn and (D) MYBPC3mut patients. E.
Heterogeneity of the cMyBP-C:α-actin staining area per patient demonstrated a signiﬁcant variability in MYBPC3mut (p= .02). F. The hypothesized consequences of
cell-to-cell variation of cMyBP-C protein expression. Diﬀerent contractile properties between each cardiomyocyte may lead to inhomogeneous contraction and
relaxation and myoﬁbrillar disarray.
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observations are in line with staining patterns of cMyBP-C protein
throughout cardiomyocyte from HCM patients with MYBPC3 muta-
tions. Cells with MYBPC3 mutation demonstrated greater disruption in
staining of thick ﬁlament proteins compared to MYH7 mutations [16].
The experiments performed in this study utilized immunoﬂuorescence
analysis on mechanically isolated single cells. With the current analysis
we were not able to quantify haploinsuﬃciency in individual cardio-
myocytes, as we did in cardiac tissue (Fig. 1). The functional con-
sequences of this variable expression of cMyBP-C remain to be de-
termined. Loss of cMyBP-C in mouse studies have shown that severe
cardiac dysfunction occurs [17]. It may be speculated that intercellular
variation of cMyBP-C protein levels lead to inhomogeneous contraction
and relaxation and may be involved in the formation of myoﬁbrillar
disarray (Fig. 2F). As aging reduces the quality of protein degradation
pathways and increases the degree of allelic imbalance in cardiomyo-
cytes [18], an age-dependent progression of cellular protein variability
may contribute to HCM development.
5. Conclusion
This is the ﬁrst study which demonstrates the intercellular variation




Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.yjmcc.2018.08.023.
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